Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.
Trim your dog or cat's nails at home with these clippers that pros recommend. Our editors and experts handpick every product we feature. We may earn a commission from your purchases. While all ...